| Code | CSB-MP008646HU |
| Abbreviation | Recombinant Human FGFR3 protein, partial (Active) |
| MSDS | |
| Size | $114 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
FGFR3 mutations drive constitutive kinase activation in multiple myeloma and bladder cancer, making the extracellular domain a critical target for therapeutic antibody development and small-molecule inhibitor screening. This mammalian-expressed construct spanning residues 23–375 captures the complete ligand-binding region and demonstrates quantifiable antibody recognition in functional ELISA, with an EC50 of 0.68–0.89 ng/mL when binding a recombinant anti-FGFR3 antibody—a result that supports its use in competitive inhibition assays, blocking antibody screening, and epitope mapping studies for biologics targeting oncogenic FGFR3 variants. The mammalian expression system preserves native glycosylation patterns essential for conformational integrity in surface plasmon resonance and biolayer interferometry experiments characterizing receptor-ligand or receptor-antibody interactions. Purity exceeding 90% and endotoxin below 1.0 EU/μg align with standards expected in therapeutic antibody validation workflows and high-throughput drug discovery campaigns.
There are currently no reviews for this product.